Table 3.
Comparison of sociodemographic, clinical, and pharmacological variables by age group for patients diagnosed with Sjögren's syndrome, Colombia.
| Variables | Total |
18–39 years |
40–64 years |
65–74 years |
≥75 years |
|||||
|---|---|---|---|---|---|---|---|---|---|---|
| n = 4945 | % | n = 284 | % | n = 2123 | % | n = 1415 | % | n = 1123 | % | |
| Woman | 3745 | 75.7 | 199 | 70.1 | 1686 | 79.4 | 1066 | 75.3 | 794 | 70.7 |
| Symptomatic treatment | 4134 | 83.6 | 237 | 83.5 | 1794 | 84.5 | 1170 | 82.7 | 933 | 83.1 |
| Oral pilocarpine | 365 | 7.4 | 18 | 6.3 | 214 | 10.1 | 96 | 6.8 | 37 | 3.3 |
| Lubricants and ocular humectants | 3966 | 80.2 | 232 | 81.7 | 1694 | 79.8 | 1122 | 79.3 | 918 | 81.7 |
| Artificial saliva | 15 | 0.3 | 0 | 0.0 | 7 | 0.3 | 4 | 0.3 | 4 | 0.3 |
| Treatment with DMARD | 605 | 12.2 | 41 | 14.4 | 357 | 16.8 | 150 | 10.6 | 57 | 5.1 |
| Convencional | 587 | 11.9 | 39 | 13.7 | 345 | 16.3 | 147 | 10.4 | 56 | 5.0 |
| Biological | 62 | 1.3 | 5 | 1.8 | 46 | 2.2 | 9 | 0.6 | 2 | 0.2 |
| Anticholinergic load | 1932 | 39.1 | 74 | 26.1 | 787 | 37.1 | 566 | 40.0 | 505 | 45.0 |
| ADS 1–2 points | 1231 | 24.9 | 49 | 17.3 | 484 | 22.8 | 366 | 25.9 | 332 | 29.6 |
| ADS ≥3 points | 701 | 14.2 | 25 | 8.8 | 303 | 14.3 | 200 | 14.1 | 173 | 15.4 |
| Symptomatic treatment + ADS ≥1 points (n = 4134) | 1629 | 39.4 | 63 | 26.6 | 666 | 37.1 | 477 | 40.8 | 423 | 45.3 |
| Symptomatic treatment + ADS 1–2 points | 1037 | 25.1 | 41 | 17.3 | 406 | 22.6 | 311 | 26.6 | 279 | 29.9 |
| Symptomatic treatment + ADS ≥3 points | 592 | 14.3 | 22 | 9.3 | 260 | 14.5 | 166 | 14.2 | 144 | 15.4 |
| Without symptomatic treatment + ADS ≥1 points (n = 811) | 303 | 37.4 | 11 | 23.4 | 121 | 36.8 | 89 | 36.3 | 82 | 43.2 |
| Without symptomatic treatment + ADS 1–2 points | 194 | 23.9 | 8 | 17.0 | 78 | 23.7 | 55 | 22.4 | 53 | 27.9 |
| Without symptomatic treatment + ADS ≥3 points | 109 | 13.4 | 3 | 6.4 | 43 | 13.1 | 34 | 13.9 | 29 | 15.3 |
| Comorbidities | 4372 | 88.4 | 194 | 68.3 | 1773 | 83.5 | 1322 | 93.4 | 1083 | 96.4 |